0001683168-23-006611.txt : 20230922 0001683168-23-006611.hdr.sgml : 20230922 20230921210803 ACCESSION NUMBER: 0001683168-23-006611 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230921 ITEM INFORMATION: Other Events FILED AS OF DATE: 20230922 DATE AS OF CHANGE: 20230921 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41282 FILM NUMBER: 231270100 BUSINESS ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 BUSINESS PHONE: 514-426-6161 MAIL ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 8-K 1 sunshine_8k.htm CURRENT REPORT
0001402328 false 0001402328 2023-09-21 2023-09-21 0001402328 us-gaap:CommonStockMember 2023-09-21 2023-09-21 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2023-09-21 2023-09-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 21, 2023

 

SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Colorado 001-41282 20-5566275

(State or other jurisdiction

of incorporation)

 (Commission File Number) (IRS Employer ID No.)

 

6500 Trans-Canada Highway

4th Floor

Pointe-Claire, Quebec, Canada H9R0A5

(Address of principal executive offices) (zip code)

 

(514) 426-6161

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Common Stock Purchase Warrants SBFMW The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 8.01 Other Events

 

As previously disclosed on March 24, 2023, Sunshine Biopharma, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). On September 21, 2023, the Company received another notification letter from Nasdaq advising that Nasdaq’s staff has determined that the Company is eligible for an extension of an additional 180 calendar day period, or until March 18, 2024, to cure the bid price deficiency. The Nasdaq staff has determined that Sunshine Biopharma is eligible for the extension based on the Company meeting the continued listing requirements for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

 

The notification has no immediate effect on the listing of the Company’s common stock. In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from September 20, 2023, or until March 18, 2024, to regain compliance with the Minimum Bid Price Requirement. If at any time before March 18, 2024, the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement.

 

The Company intends to continue actively monitoring the bid price for its common stock between now and March 18, 2024, and will consider all available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement, including the effecting of a reverse stock split, if necessary.

 

On September 21, 2023 the Company issued a press release regarding this notification. A copy of the press release is attached as Exhibit 99.1 hereto.

 

Item 9.01 Financial Statements and Exhibits

 

(b) Exhibits

 

The following exhibits are included in this report:

 

No. Description
99.1 Press Release issued on September 21, 2023
104 Cover Page Interactive Data File (formatted in iXBRL)

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 21, 2023 SUNSHINE BIOPHARMA, INC.
   
   
  By: /s/ Dr. Steve N. Slilaty                          
  Dr. Steve N. Slilaty, Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 3 
 EX-99.1 2 sunshine_ex9901.htm PRESS RELEASE

Exhibit 99.1

 

 

For Immediate Release

September 21, 2023

 

 

SUNSHINE BIOPHARMA RECEIVES 180-DAY EXTENSION TO ACHIEVE NASDAQ MINIMUM BID COMPLIANCE

 

No Immediate Effect on Nasdaq Listing or Trading of the Company's Common Stock

 

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has received a 180-day extension, until March 18, 2024, to achieve compliance with the Nasdaq $1.00 minimum bid price rule. The Nasdaq staff has determined that Sunshine Biopharma is eligible, based on the Company meeting the continued listing requirements for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

 

If at any time before March 18, 2024, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed.

 

This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's common stock, which will continue to trade on the Nasdaq Capital Market under the symbol "SBFM."

 

About Sunshine Biopharma

 

Sunshine Biopharma recently acquired Nora Pharma Inc. and as a result the Company now has 50 generic prescription drugs on the market in Canada and 41 additional employees. The Company is planning to expand its product offering to 77 generic prescription drugs over the next 18 months. In parallel, Sunshine Biopharma is continuing its proprietary drug development program which is comprised of (i) K1.1 mRNA for liver cancer, (ii) Adva-27a, a small chemotherapy molecule for pancreatic cancer, and (iii) PLpro protease inhibitor for COVID-19. For more information, please visit: www.sunshinebiopharma.com.

 

Safe Harbor Forward-Looking Statements

 

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the “Company”) that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company’s drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’s filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recent SEC filings.

 

For Additional Information:

 

Sunshine Biopharma Contact:

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

 

 EX-101.SCH 3 sbfm-20230921.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 sbfm-20230921_def.xml XBRL DEFINITION FILE EX-101.LAB 5 sbfm-20230921_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Common Stock Purchase Warrants [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 sbfm-20230921_pre.xml XBRL PRESENTATION FILE GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Sep. 21, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 21, 2023
Entity File Number 001-41282
Entity Registrant Name SUNSHINE BIOPHARMA, INC.
Entity Central Index Key 0001402328
Entity Tax Identification Number 20-5566275
Entity Incorporation, State or Country Code CO
Entity Address, Address Line One 6500 Trans-Canada Highway
Entity Address, Address Line Two 4th Floor
Entity Address, City or Town Pointe-Claire
Entity Address, State or Province QC
Entity Address, Country CA
Entity Address, Postal Zip Code H9R0A5
City Area Code (514)
Local Phone Number 426-6161
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol SBFM
Security Exchange Name NASDAQ
Common Stock Purchase Warrants [Member]  
Title of 12(b) Security Common Stock Purchase Warrants
Trading Symbol SBFMW
Security Exchange Name NASDAQ
XML 9 sunshine_8k_htm.xml IDEA: XBRL DOCUMENT 0001402328 2023-09-21 2023-09-21 0001402328 us-gaap:CommonStockMember 2023-09-21 2023-09-21 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2023-09-21 2023-09-21 iso4217:USD shares iso4217:USD shares 0001402328 false 8-K 2023-09-21 SUNSHINE BIOPHARMA, INC. CO 001-41282 20-5566275 6500 Trans-Canada Highway 4th Floor Pointe-Claire QC CA H9R0A5 (514) 426-6161 Common Stock, par value $0.001 SBFM NASDAQ Common Stock Purchase Warrants SBFMW NASDAQ false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sunshinebiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sbfm-20230921.xsd sbfm-20230921_def.xml sbfm-20230921_lab.xml sbfm-20230921_pre.xml sunshine_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sunshine_8k.htm": { "nsprefix": "SBFM", "nsuri": "http://sunshinebiopharma.com/20230921", "dts": { "schema": { "local": [ "sbfm-20230921.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "sbfm-20230921_def.xml" ] }, "labelLink": { "local": [ "sbfm-20230921_lab.xml" ] }, "presentationLink": { "local": [ "sbfm-20230921_pre.xml" ] }, "inline": { "local": [ "sunshine_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://sunshinebiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-09-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "SBFM_CommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20230921", "localname": "CommonStockPurchaseWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001683168-23-006611-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-23-006611-xbrl.zip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